Breast Cancer Liquid Biopsy Market Trend Analysis Research Report By Product (Consumables, Kits), By Biomarkers (Extracellular Vehicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers), By Application (Early Detection Or Screening, Diagnosis, Other Applications), By End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories), and by Region - Global Forecast to 2034
May-2025 Formats | PDF | Category: Healthcare | Delivery: 24 to 72 Hours
“The Breast Cancer Liquid Biopsy Market industry is expected to expand from $ 0.93 Billion in 2025 to $ 2.34 Billion in 2034, with a compound annual growth rate of 15.2%. “
Breast Cancer Liquid Biopsy Market: Overview and Growth in the Upcoming Year
The increasing use of liquid biopsies for breast cancer surveillance and early detection is expected to drive a significant increase in the market for these procedures in the upcoming year. Real-time disease monitoring and therapy response evaluation are made possible by liquid biopsy, a less invasive and uncomfortable alternative to traditional tissue biopsy. As a result, more and more breast cancer patients are asking for liquid biopsy testing.
Among other advancements in liquid biopsy technology, the development of more sensitive and accurate biomarkers for breast cancer is driving market growth. These technological advancements have improved the accuracy and reliability of liquid biopsy tests, making them more accessible and affordable for patients. Furthermore, the demand for liquid biopsy testing is expected to rise in the upcoming year due to the rising incidence of breast cancer worldwide.
Furthermore, it is projected that the growing interest and funding in precision medicine and tailored cancer treatment will lead to an expansion of the market for liquid biopsies for breast cancer. Liquid biopsy testing allows oncologists to tailor treatment plans that target the underlying causes of the disease by detecting specific genetic mutations and molecular abnormalities in each patient. The increasing acceptance of this customized approach to cancer treatment by patients and medical professionals is driving the use of liquid biopsy testing.
The global market for liquid biopsies for breast cancer is also benefiting from increased collaboration and partnerships among biotechnology companies, diagnostic labs, and research institutes. These collaborations are helping to develop new liquid biopsy tests and expanding the availability of liquid biopsy testing in many regions. This will help address the unmet needs of breast cancer patients, especially in remote or underprivileged areas where access to traditional biopsy methods may be limited.
In conclusion, a number of factors, such as technological advancements, the growing demand for customized cancer care, and collaborations among industry players, are anticipated to contribute to the significant growth of the liquid biopsies market for breast cancer over the course of the next year. The market is expected to continue expanding as more patients and medical professionals learn about the benefits of liquid biopsy testing for early detection and monitoring of breast cancer. Because of ongoing research and development efforts as well as government funding for cancer screening programs, the market for liquid biopsies is expected to grow steadily over the course of the upcoming year and beyond.
Latest Report, titled “Breast Cancer Liquid Biopsy Market” Trends, Share, Size, Growth, Opportunity and Forecast 2025-2034, by For Insights Consultancy offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Breast Cancer Liquid Biopsy market has been expanding significantly in recent years, driven by various key factors like increased demand for its products, expanding customer base, and technological advancements. This report provides a comprehensive analysis of the Breast Cancer Liquid Biopsy market, including market size, trends, drivers and constraints, competitive aspects, and prospects for future growth.
Overview and Scope of the Report:
This report is centred around the Breast Cancer Liquid Biopsy in the worldwide market, with a specific focus on North America, Europe, Asia-Pacific, South America, Middle East, and Africa. The report classifies the market by manufacturers, regions, type, and application. It presents a comprehensive view of the current market situation, encompassing historical and projected market size in terms of value and volume. Additionally, the report covers technological advancements and considers macroeconomic and governing factors influencing the market.
Key Players Covered In This Report:
- Johnson & Johnson Private Limited
- Roche Diagnostics
- Merck KGaA
- Thermo Fisher Scientific
- Siemens Healthineers
- Agilent Technologies Inc.
- Illumina Inc.
- Sysmex Corporation
- Qiagen N.V.
- Myriad Genetics Inc.
- NeoGenomics Laboratories
- Guardant Health Inc.
- Twist Bioscience
- Foundation Medicine Inc.
- Biodesix Inc.
- Menarini Silicon Biosystems
- Datar Cancer Genetics
- Abcam plc
- OncoDNA SA
- Genomic Health Inc.
- RainDance Technologies
- Biocept Inc.
- Fluxion Biosciences Inc.
- Angle plc
This Report includes a company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The data points provided are only related to the company’s focus related to Breast Cancer Liquid Biopsy markets. Leading Breast Cancer Liquid Biopsy market players and manufacturers are studied to give a brief idea about competitions.
Industry News
May 28, 2024 Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
Merck known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC). At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were observed. Results will be presented at an upcoming medical meeting and shared with regulatory authorities.
Global Breast Cancer Liquid Biopsy Market Segments:
Segment By Product
- Consumables
- Kits
Segment By Biomarkers
- Extracellular Vesicles (EVs)
- Cell-free DNA (cfDNA)
- Circulating Tumor RNA (ctRNA)
- Circulating Tumor Cells (CTCs)
- Cell-free RNA (cfRNA)
- Other Biomarkers
Segment By Application
- Early Detection Or Screening
- Diagnosis
- Other Applications
Segment By End-Users
- Laboratories
- Hospitals
- Physician Laboratories
- Reference Laboratories
- Public Health Laboratories
- Research Institutes
- Small Molecular Laboratories
- Pathology Laboratories
Subsegments:
By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits
Regional Deep-dive Analysis:
The report provides in-depth qualitative and quantitative data on the Breast Cancer Liquid Biopsy Market for all of the regions and countries listed below:
- North America includes the United States, Canada, and Mexico.
- Europe includes Germany, France, Italy, the United Kingdom, Scandinavia, Benelux, Russia, and the rest of Europe.
- Asia-Pacific includes Japan, South Korea, India, China, Southeast Asia, and Australia.
- South America (including Brazil, Argentina, and the rest of South America)
- Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa)
Each country is studied in detail, and the study includes qualitative and quantitative analysis of the Breast Cancer Liquid Biopsy Market in that country.
North America
Although North America dominates the global market for breast cancer liquid biopsies, the United States accounts for a sizeable share of this market. At a compound annual growth rate (CAGR) of 23.0%, the U.S. market is predicted to grow from its 2024 valuation of USD 106.25 million to USD 842.13 million by 2034. The primary forces behind this growth are the existence of significant companies like Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., and NeoGenomics Laboratories, as well as quick technological advancements and encouraging government regulations.
Europe
Europe is now a major player in the breast cancer liquid biopsy market thanks to the expanding use of customized therapy and regulatory support for liquid biopsy technologies. More than 355,000 new cases of breast cancer are reported in the region each year.
France: The French market is expected to generate USD 44.3 million in revenue in 2024 and USD 74.4 million by 2030, with a compound annual growth rate (CAGR) of 9%.
United Kingdom: The UK market is anticipated to grow at a CAGR of 9.9% to reach USD 76.8 million by 2030.
Asia-Pacific
Due to rising cancer rates and rising medical costs, the Asia Pacific region’s market for breast cancer liquid biopsies is growing rapidly. In 2020, the region saw over 950,000 new cases of breast cancer, the majority of which were in China and India.
China: The growing incidence of breast cancer and the increased need for accurate diagnostics are driving the market’s expansion.
Japan: Japan is a leader in the adoption of advanced diagnostic technology, with initiatives to integrate AI into liquid biopsy platforms.
Middle East and Africa
The Middle East area is gradually embracing liquid biopsy technology despite constraints connected to healthcare infrastructure. With roughly 120,000 new cases each year, breast cancer is the most common cancer among women in this area.
Saudi Arabia: From its 2024 revenue of USD 6.5 million to USD 9.1 million by 2030, the market is expected to grow at a compound annual growth rate (CAGR) of 5.8%. Access to cancer testing will increase as a result of the government’s increased funding for medical facilities and state-of-the-art diagnostic tools.
United Arab Emirates (UAE): The UAE is predicted to have a market value of USD 6.4 million by 2030, making it the fastest-growing regional market in the Middle East and Africa.
Key Opportunities:
The report examines the key opportunities in the Breast Cancer Liquid Biopsy Market and identifies the factors that are driving and will continue to drive the industry’s growth. It takes into account past growth patterns, growth drivers, as well as current and future trends.
Highlights of Our Report:
Extensive Market Analysis: A deep dive into the manufacturing capabilities, production volumes, and technological innovations within the Breast Cancer Liquid Biopsy Market.
Corporate Insights: An in-depth review of company profiles, spotlighting major players and their strategic manoeuvres in the market’s competitive arena.
Consumption Trends: A detailed analysis of consumption patterns, offering insight into current demand dynamics and consumer preferences.
Segmentation Details: An exhaustive breakdown of end-user segments, depicting the market’s spread across various applications and industries.
Pricing Evaluation: A study of pricing structures and the elements influencing market pricing strategies.
Future Outlook: Predictive insights into market trends, growth prospects, and potential challenges ahead.
Why Should You Obtain This Report?
Statistical Advantage: Gain access to vital historical data and projections for the Breast Cancer Liquid Biopsy Market, arming you with key statistics.
Competitive Landscape Mapping: Discover and analyze the roles of market players, providing a panoramic view of the competitive scene.
Insight into Demand Dynamics: Obtain comprehensive information on demand characteristics, uncovering market consumption trends and growth avenues.
Identification of Market Opportunities: Astutely recognize market potential, aiding stakeholders in making informed strategic decisions.
Questions Answered by the Report:
(1) Which are the dominant players of the Breast Cancer Liquid Biopsy Market?
(2) What will be the size of the Breast Cancer Liquid Biopsy Market in the coming years?
(3) Which segment will lead the Breast Cancer Liquid Biopsy Market?
(4) How will the market development trends change in the next five years?
(5) What is the nature of the competitive landscape of the Breast Cancer Liquid Biopsy Market?
(6) What are the go-to strategies adopted in the Breast Cancer Liquid Biopsy Market?
Customization: We can provide following things
1) On request more company profiles (competitors)
2) Data about particular country or region
3) We will incorporate the same with no additional cost (Post conducting feasibility).
Any Requirement Contact us:https://forinsightsconsultancy.com/contact-us/
Table of Contents
For TOC Contact us: https://forinsightsconsultancy.com/contact-us/
Select PDF License
Single User: $3499
Multiple Users: $4499
Corporate Users: $5499
